Articles tagged with Vaccination
A Mayo Clinic study analyzed data from the Rochester Epidemiology Project and found a stable incidence of autism until 1988-1991, then increased with new diagnostic criteria and special education laws. Researchers identified 124 children meeting current diagnostic criteria for autism out of 3,000 with related diagnoses.
Researchers developed a probability model to predict how many cases of anthrax could be prevented under varying conditions. The study found that antibiotics distributed within 6 days after exposure and taken for 60 days can prevent up to 70% of anthrax cases.
Researchers from CANVAC, a Canadian network of immunology and virology experts, have developed a new method to assess thymus function using only blood samples. They found that HIV-infected individuals experience decreased thymic function in the first months after infection, leading to lower T-lymphocyte production.
UT Southwestern researchers developed a gene-based vaccine to stimulate immune systems against amyloid protein, reducing plaque buildup and cognitive loss in mice. The study aims to create a safe and effective Alzheimer's vaccine that can prevent or slow disease progression.
A four-year study by Yale researchers found that vaccinating white-footed mice reduced the number of deer ticks carrying Lyme disease. The study demonstrated a significant reduction in risk for humans getting Lyme disease from tick bites, but not as great as expected. Further development of oral vaccines is proposed to reduce human risk.
Researchers developed a new live rabies vaccine by manipulating the virus, making it weaker and more effective in provoking an immune response. The vaccine has shown promise in preventing the spread of rabies in wildlife and humans, with potential applications for stray dogs and animals.
Researchers have developed a peptide vaccine that produces an immune response in 60% of patients with myeloid leukemia, resulting in complete molecular remission for three patients. The vaccine targets the PR1 peptide, which is overexpressed on leukemia cells, inducing immune T-cells to kill cancer cells while leaving normal cells intact.
A Stanford researcher has developed a test that reverses pre-existing food allergies in dogs by vaccinating them with heat-killed bacteria mixed with peanuts or milk. The test showed significant results, with four dogs able to eat over 37 peanuts and five dogs tolerating larger quantities of milk without symptoms.
A randomized trial has demonstrated that a HPV vaccine is effective in preventing persistent HPV infections, abnormal Pap tests, and precancerous lesions. The vaccine's efficacy rate is up to 95%, suggesting a substantial reduction in cervical cancer rates globally.
Researchers aim to block harmful immune response in brain inflammation and remove beta amyloid plaques with anti-CD40 ligand antibody and investigational vaccine. The study builds on previous USF laboratory studies tracking the role of microglia in Alzheimer's disease.
A new pertussis booster vaccine candidate has shown promising results in a clinical trial, providing extended protection against whooping cough, diphtheria, and tetanus for adolescents. The vaccine, Boostrix, demonstrated high levels of anti-pertussis antibodies and comparable side effects to the existing Td vaccine.
Researchers analyzed VAERS data for adverse events following pneumococcal conjugate vaccine (PCV) vaccination in children. The study found that 13.2 reports of events were submitted per 100,000 doses distributed.
A new report highlights the potential of biotechnologies in improving health in developing countries. The report proposes a global institute to share and promote the benefits of genomic sciences, aiming to save tens of millions of lives per year.
A research team led by Peter B. Jahrling has successfully developed a nonhuman primate model of smallpox infection in monkeys. The study demonstrates that variola virus can produce lethal disease in monkeys, providing valuable insight into the pathogenesis of smallpox.
Mayo Clinic has been awarded a major NIH contract to conduct genomic research on smallpox vaccination, utilizing its advanced genomics technology center and biostatisticians. The study aims to identify gene polymorphisms affecting susceptibility to infection and response to vaccination.
A recent study using the General Practice Research Database found an association between hepatitis B vaccination and a three-fold increase in MS incidence within three years following vaccination. The study's limitations highlight the need for further research into the potential link between vaccines and autoimmune diseases.
A recent UK study published in The Lancet has found no association between the MMR vaccine and the development of autism or pervasive developmental disorders. Researchers analyzed data from over 1,300 cases and 4,469 controls, concluding that vaccination did not increase the risk of these conditions.
A new study by Vanderbilt University Medical Center shows the pneumococcal conjugate vaccine significantly decreases illnesses in children under 2 years old. The vaccine has been found to reduce ear infections and pneumonia cases by 7% and 17%, respectively, resulting in fewer doctor visits and cost savings.
Researchers found that a frozen preparation of smallpox vaccine remained effective even at 10-fold diluted doses. The study involved 340 healthy volunteers and showed a high vaccination success rate, suggesting the vaccine can be safely expanded for use in emergency situations or during public health crises.
A new pediatric croup vaccine has been shown to be safe and well-tolerated in adults, with no significant reactions or laboratory abnormalities. The vaccine contains a live virus that stimulates both antibody and cellular immune responses, providing potential durable protection against hPIV-1.
The study found that USAMRIID's biosafety and medical management program effectively prevented laboratory-acquired infections, with only five confirmed cases in a fourteen-year period. The review emphasized the importance of vaccination and early evaluation of potential exposures.
Researchers found that activation of Serine protease inhibitor 2A (Spi2A) can prevent T cell death and increase memory T cells, potentially boosting vaccine efficacy. This discovery could lead to new vaccines or treatments for chronic infections and autoimmune diseases.
Researchers at Cedars-Sinai Medical Center found that combining an anti-tumor vaccine with chemotherapy significantly extended patient survival to 26 months on average. The treatment, which involves dendritic-cell immunotherapy, was shown to slow tumor growth and increase the effectiveness of chemotherapy.
A phase 1 vaccine trial has demonstrated that a group A streptococcal vaccine appears safe and well-tolerated, inducing immune responses capable of conferring protection against multiple strains. The study's findings suggest that a specific dose and schedule may be effective in preventing group A streptococcal infections.
A study found that vaccinated cases were half as contagious as unvaccinated cases, with varying levels of contagiousness depending on the number of lesions. The authors suggest continued monitoring to improve vaccine policy decisions for future generations.
A survey of mothers reveals that they view pediatricians as 'parenting partners' and carefully select a doctor for their child. Key findings include the importance of personality, health insurance coverage, and compatibility with parenting objectives in choosing a pediatrician.
A novel protein vaccine candidate has demonstrated full protection against a lethal aerosol challenge with ricin toxin in mice, offering a promising solution to bioterrorism threats. The vaccine, RTA 1-33/44-198, was designed using molecular modeling and protein engineering techniques.
Researchers used glycan microarrays to explore novel immunologic targets for SARS-CoV. The study found undesired autoantibody reactivity against human serum glycoprotein ASOR, prompting concerns over the safety of whole-viral SARS vaccines.
A new breed of vaccine-producing plants is being developed to combat global health issues, including cholera and diarrhea. The innovative technology uses minimal processing to yield heat-stable vaccines for oral delivery.
Researchers will investigate the link between atopic dermatitis and severe skin reaction EV in a nationwide research network. The study aims to better understand how atopic dermatitis predisposes individuals to EV after smallpox vaccination.
OHSU researchers are studying vaccination methods for seniors and children, with a focus on developing protection against infectious diseases. The study aims to understand immune system changes that occur with aging and develop methods to manipulate the system for better protection.
Scientists at the University of Rochester Medical Center created an Alzheimer's vaccine with a customizable immune response using a harmless form of the herpes virus. The modified vaccine proved safer while still causing a 20-percent decline in amyloid plaque in the brain, offering new hope for developing a safe and effective vaccine.
Researchers warn that live flavivirus vaccines can recombine, resulting in new microbes with undesirable properties. The use of these vaccines requires international approval due to safety concerns, including increased virulence, disease development in compromised individuals, and birth defects.
Researchers have identified proteins that determine which mice succumb to mousepox and which do not. Strains resistant to infection produce type-1 cytokines, while susceptible ones produce type-2 cytokine IL-4. The discovery could enable better protection for humans against smallpox.
Researchers have made significant progress in developing a therapeutic vaccine for pancreatic cancer, which appears safe and stimulates immune activity. In a recent study, 12 patients with pancreatic cancer received the vaccine, resulting in no reported toxicity and positive changes in antibodies against the tumor.
Researchers at Thomas Jefferson University have made significant progress in developing a new vaccine against malignant melanoma, a potentially deadly skin cancer. The vaccine showed promise in a phase I-II study, with 8 of 10 patients developing positive responses to their own tumor cells that were chemically modified.
A phase II multicenter study evaluated a multiepitope CD8 T-cell vaccine for metastatic melanoma patients, demonstrating an immune response associated with longer survival. The vaccine showed promising results in stimulating an immune response, but no correlation was found with clinical tumor responses.
Researchers at Cedars-Sinai Medical Center have developed a new approach to boost the immune response against gliomas, a type of brain tumor. By targeting the interleukin 10 gene in dendritic cells, they can increase the production of IL-12, leading to a stronger Th1 response and enhanced immune response against cancer cells.
Researchers have developed a new vaccine strategy using live, crippled Salmonella bacteria that stimulate immunity to multiple pathogens. The vaccine protected mice 100% against lethal doses of both S. typhimurium and Listeria monocytogenes.
The NIH has awarded $20.7 million to create a safer smallpox vaccine for individuals with atopic dermatitis, a condition that makes them susceptible to serious reactions. Researchers will conduct both laboratory and clinical studies to understand the disease and develop protocols to safely vaccinate these patients.
The ADVN aims to understand immune responses in AD patients after natural exposure to skin viruses and investigate their reactions to the smallpox vaccine. The network will inform safer vaccine design, improving protection against the smallpox virus without life-threatening complications.
The temporary suspension of the hepatitis B vaccine at birth due to mercury concerns led to a significant decrease in first-day vaccination coverage. The study found that 11% of children born during the suspension were not vaccinated on their first day, resulting in an excess of 182,000 undervaccinated children by 19 months.
The Department of Defense Smallpox Vaccination Program reported over 50 cases of myopericarditis, a heart muscle inflammation, following vaccination. Most soldiers experiencing complications have recovered well with therapy, but researchers stress the need for further study to better understand potential cardiac risks.
Researchers at Brookhaven National Laboratory have deciphered the structure of botulinum toxin, shedding light on its mechanism of action. By modifying a single amino acid, scientists created an inactive form of the toxin that retains structural similarity to the active form, paving the way for potential vaccine development.
Scientists are developing a new anthrax vaccine that requires fewer shots and has fewer side effects. The study aims to improve upon the existing vaccine, which causes numerous side effects and takes 18 months to confer protection.
A new investigational anthrax vaccine is being tested in a phase II human study at Saint Louis University. The vaccine aims to provide better protection, an improved safety profile and a simpler dosing schedule.
Drs. Thal and Nitsch receive the Potamkin Prize for their groundbreaking research on effective therapies to treat and prevent Alzheimer's disease. Their work has revitalized hopes for a vaccine and slowed cognitive decline in patients.
A survey of oncologists and nurses found that while most agree to offer trial results to patients, only 62% actually do so due to concerns over potential negative effects, patient interpretation, and resource consumption. Additionally, a new study demonstrates tamoxifen's association with reduced breast density, particularly in younger...
A study found that HIV-positive US military personnel who received a smallpox vaccine between 2002-2003 showed no negative effects. The researchers suggest exempting HIV-infected individuals from vaccination during outbreaks, but consider weakened vaccines for immunocompromised people in the future.
Researchers equipped dendritic cells with genetic material from patient's tumor and PAMPs to break T-cell tolerance, enabling activation of immune system. This approach merges strengths of viral vaccines with ease of using patient's own immune system.
A recent study examined 350 adult volunteers and found that 3.6% developed harmless skin rashes after vaccination. The rashes cleared up on their own within one to three weeks without serious symptoms.
A new dental caries vaccine is being proposed as a crucial tool to prevent the spread of tooth decay, particularly in vulnerable populations. The symposium emphasizes the vaccine's potential to combat the disease and its impact on public health.
A team of scientists has successfully tested a new smallpox vaccine that shows promise as an alternative to the existing Dryvax vaccine. The MVA vaccine was found to elicit equivalent or higher immune responses in nonhuman primates, providing protection against monkeypox.
Researchers developed a topical vaccine that induces high levels of anti-ricin immune responses in mice, with 70% survival rate upon lethal challenge. The vaccine candidate offers a viable alternative delivery route for ricin poisoning treatment.
The Phase I study demonstrated a clear dose-response relationship between the amount of rPA102 administered and the subsequent immune response, with antibody titers continuing to increase after the second and third administration. The vaccine was well-tolerated, with no evidence of dose-limiting toxicity or reactogenicity at any dose.
Researchers develop vaccine that prevents tumor growth in mice, while also reversing cardiac dysfunction through gene therapy. These breakthroughs demonstrate the potential of combinatorial approaches to vaccination and gene therapy for treating neoplastic lesions and heart disease.
A new vaccine has been shown to halt HER-2/neu preneoplastic breast cancer lesions through both morphologic and gene expression data. The findings suggest a potential breakthrough in the treatment of this type of cancer, according to a recent study published in JCI Journals.
A new vaccine has shown significant improvement in 5-year progression-free survival rates for patients with renal cancer, with a 77% rate in the vaccinated group compared to 68% in the control group. The well-tolerated treatment was associated with only 12 adverse events.
The study found that the chickenpox vaccine's effectiveness decreases significantly after one year, with 97% efficacy in the first year and 84% in subsequent years. The vaccine's effectiveness was lower for children under 15 months old, with a 73% efficacy rate.
Dr. Offit reviews scientific evidence on vaccine safety, finding no link between vaccines and weakened immune systems, allergic or autoimmune diseases, or mercury injury. The Vaccine Education Center provides up-to-date science-based information on vaccines and preventable diseases.